Calprotectin is a protein complex from the S-100 family, which is formed of three polypeptide chains, two heavy and one light 2. It was first purified in 1980 and called L1 protein by the group that discovered it, although like many proteins has had multiple names, and calprotectin is now preferred 2.
It is found in especially heavy concentrations in neutrophils and monocytes, and more generally within skin cells, with an organ distribution including the lungs, gastrointestinal tract, oral and cervical mucosae and associated body fluids/secretions.
During the inflammatory process it is secreted by neutrophils and macrophages in the gut and is assayable in the feces.
There are many commercially-available testing kits for calprotectin, the majority using ELISA (enzyme-linked immunosorbent assay) techniques.
Fecal calprotectin is primarily employed in two scenarios:
- distinguish inflammatory bowel disease from irritable bowel syndrome
- assess disease activity in inflammatory bowel disease, including acute exacerbations and response to treatment
The use of fecal calprotectin as a screening tool for colorectal carcinoma has been explored however its specificity is too low to be useful in the general population 1.
No consensus exists on the correlation between calprotectin levels and activity of bowel disease on cross-sectional imaging, as studies have come to different conclusions, a recent study, albeit a small cohort, showed a weak correlation at best 4.
- 1. Kronborg O, Ugstad M, Fuglerud P, Johne B, Hardcastle J, Scholefield JH, Vellacott K, Moshakis V, Reynolds JR. Faecal calprotectin levels in a high risk population for colorectal neoplasia. (2000) Gut. 46 (6): 795-800. Pubmed
- 2. Johne B, Fagerhol MK, Lyberg T, Prydz H, Brandtzaeg P, Naess-Andresen CF, Dale I. Functional and clinical aspects of the myelomonocyte protein calprotectin. (1997) Molecular pathology : MP. 50 (3): 113-23. Pubmed
- 3. National Institute for Health and Care Excellence (2013) Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel. NICE diagnostics guidance [DG11]
- 4. Abej E, El-Matary W, Singh H, Bernstein CN. The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease. (2016) Canadian journal of gastroenterology & hepatology. 2016: 2483261. doi:10.1155/2016/2483261 - Pubmed